

John P H Wilding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8540760/publications.pdf>

Version: 2024-02-01

341
papers

36,187
citations

8732

75
h-index

3476

182
g-index

361
all docs

361
docs citations

361
times ranked

27234
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 380, 347-357.	13.9	4,159
2	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
3	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , The, 2019, 393, 31-39.	6.3	1,958
4	A role for glucagon-like peptide-1 in the central regulation of feeding. <i>Nature</i> , 1996, 379, 69-72.	13.7	1,692
5	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. <i>New England Journal of Medicine</i> , 2015, 373, 11-22.	13.9	1,492
6	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021, 384, 989-1002.	13.9	1,374
7	Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. <i>Obesity Reviews</i> , 2017, 18, 715-723.	3.1	846
8	Management of obesity. <i>Lancet</i> , The, 2016, 387, 1947-1956.	6.3	715
9	Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1020-1031.	1.8	689
10	Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. <i>European Heart Journal</i> , 2004, 25, 735-741.	1.0	683
11	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Circulation</i> , 2017, 136, 249-259.	1.6	672
12	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet</i> , The, 2015, 385, 2067-2076.	6.3	659
13	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
14	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet</i> , The, 2017, 389, 1399-1409.	6.3	502
15	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 606-617.	5.5	482
16	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
17	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 637-649.	6.3	446
18	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2528-2536.	1.6	415

#	ARTICLE	IF	CITATIONS
19	Food Fails to Suppress Ghrelin Levels in Obese Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2984-2984.	1.8	411
20	Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin. <i>Annals of Internal Medicine</i> , 2012, 156, 405.	2.0	402
21	Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 159-169.	2.2	391
22	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2628-2639.	1.2	370
23	Anti-obesity drugs: past, present and future. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 621-626.	1.2	360
24	A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers. <i>Diabetes Care</i> , 2009, 32, 1656-1662.	4.3	346
25	Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. <i>Archives of Internal Medicine</i> , 2000, 160, 1321.	4.3	312
26	Hypothalamic orexin expression: modulation by blood glucose and feeding. <i>Diabetes</i> , 1999, 48, 2132-2137.	0.3	286
27	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. <i>International Journal of Clinical Practice</i> , 2013, 67, 1267-1282.	0.8	281
28	Cardiovascular and metabolic effects of CPAP in obese males with OSA. <i>European Respiratory Journal</i> , 2007, 29, 720-727.	3.1	278
29	Sleep-disordered breathing and type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, 2-12.	1.1	276
30	Vitamin D signalling in adipose tissue. <i>British Journal of Nutrition</i> , 2012, 108, 1915-1923.	1.2	261
31	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 597-609.	5.5	248
32	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1227-1234.	1.6	241
33	Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. <i>Postgraduate Medical Journal</i> , 2006, 82, 280-284.	0.9	240
34	Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 124-136.	2.2	239
35	Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 34-42.	1.8	225
36	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019, 139, 2516-2527.	1.6	224

#	ARTICLE	IF	CITATIONS
37	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <i>Lancet</i> , The, 2021, 398, 262-276.	6.3	222
38	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 27-35.	5.5	215
39	The importance of weight management in type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2014, 68, 682-691.	0.8	209
40	A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. <i>International Journal of Obesity</i> , 2004, 28, 1399-1410.	1.6	194
41	A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1696-1704.	1.2	193
42	Gut peptides and the regulation of appetite. <i>Obesity Reviews</i> , 2006, 7, 163-182.	3.1	190
43	Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 990-999.	2.2	176
44	Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes. <i>Endocrinology</i> , 2009, 150, 1688-1696.	1.4	161
45	Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. <i>BMJ</i> , The, 2014, 349, g6608-g6608.	3.0	158
46	Neuropeptides and appetite control. <i>Diabetic Medicine</i> , 2002, 19, 619-627.	1.2	155
47	The importance of free fatty acids in the development of Type 2 diabetes. <i>Diabetic Medicine</i> , 2007, 24, 934-945.	1.2	153
48	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1553-1564.	2.2	151
49	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. <i>Obesity</i> , 2020, 28, 1050-1061.	1.5	148
50	Dietary Advice Based on the Glycaemic Index Improves Dietary Profile and Metabolic Control in Type 2 Diabetic Patients. <i>Diabetic Medicine</i> , 1994, 11, 397-401.	1.2	147
51	SPARC: a key player in the pathologies associated with obesity and diabetes. <i>Nature Reviews Endocrinology</i> , 2010, 6, 225-235.	4.3	141
52	The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1228-1237.	1.5	139
53	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. <i>Obesity Reviews</i> , 2019, 20, 816-828.	3.1	139
54	Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. <i>British Journal of Pharmacology</i> , 1999, 128, 1570-1576.	2.7	132

#	ARTICLE	IF	CITATIONS
55	An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. <i>Clinical Endocrinology</i> , 2001, 54, 463-468.	1.2	121
56	Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 755-761.	2.2	119
57	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1183-1187.	2.9	118
58	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)â€“TIMI 58 Trial. <i>American Heart Journal</i> , 2018, 200, 83-89.	1.2	117
59	A parametric analysis of olanzapine-induced weight gain in female rats. <i>Psychopharmacology</i> , 2005, 181, 80-89.	1.5	115
60	SGLT-2 Inhibitors and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2497-2506.	1.2	113
61	Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose. <i>Diabetes</i> , 2009, 58, 1780-1788.	0.3	108
62	Economic impacts of overweight and obesity: current and future estimates for eight countries. <i>BMJ Global Health</i> , 2021, 6, e006351.	2.0	107
63	Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a doseâ€“finding study. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 403-409.	2.2	103
64	The adipokine zincâ€“2â€“glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. <i>Clinical Endocrinology</i> , 2010, 72, 334-341.	1.2	102
65	Glucagonâ€“like peptideâ€“1 (GLPâ€“1): a trial of treatment in nonâ€“insulinâ€“dependent diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 1997, 27, 533-536.	1.7	98
66	<scp>DECLAREâ€“TIMI</scp> 58: Participantsâ€™ baseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1102-1110.	2.2	96
67	Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. <i>Journal of Psychopharmacology</i> , 2007, 21, 405-413.	2.0	95
68	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 1569-1577.	1.6	94
69	What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. <i>International Journal of Obesity</i> , 2017, 41, 853-865.	1.6	93
70	Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 1282-1294.	2.9	91
71	1,25-dihydroxyvitamin D3 Protects against Macrophage-Induced Activation of NFÎ±B and MAPK Signalling and Chemokine Release in Human Adipocytes. <i>PLoS ONE</i> , 2013, 8, e61707.	1.1	88
72	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88

#	ARTICLE	IF	CITATIONS
73	Early Weight Loss with Liraglutide 3.0 mg Predicts 1â€Year Weight Loss and is Associated with Improvements in Clinical Markers. <i>Obesity</i> , 2016, 24, 2278-2288.	1.5	88
74	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2210-2219.	2.2	87
75	Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. <i>Journal of Endocrinology</i> , 1992, 132, 299-304.	1.2	82
76	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 268-273.	1.2	76
77	Energy balance and metabolic changes with sodiumâ€glucose coâ€transporter 2 inhibition. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 125-134.	2.2	76
78	Doseâ€ranging study with the glucokinase activator <scp>AZD1656</scp> in patients with type 2 diabetes mellitus on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 750-759.	2.2	74
79	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	4.3	72
80	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. <i>Diabetic Medicine</i> , 2004, 21, 415-422.	1.2	71
81	The dual PPARÎ± /Î³ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. <i>British Journal of Pharmacology</i> , 2005, 144, 308-316.	2.7	71
82	Increases in Neuropeptide Y Content and Gene Expression in the Hypothalamus of Rats Treated with Dexamethasone Are Prevented by Insulin. <i>Neuroendocrinology</i> , 1993, 57, 581-587.	1.2	70
83	A review of the mechanism of action, metabolic profile and haemodynamic effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 9-18.	2.2	69
84	Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. <i>Molecular Brain Research</i> , 2000, 77, 131-137.	2.5	68
85	Hypothalamic obesity in humans: what do we know and what can be done?. <i>Obesity Reviews</i> , 2002, 3, 27-34.	3.1	66
86	Rates of myocardial infarction and stroke in patients initiating treatment with <scp>SGLT</scp>2â€inhibitors versus other glucoseâ€lowering agents in realâ€world clinical practice: <scp>R</scp>esults from the <scp>CVDâ€REAL</scp> study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1983-1987.	2.2	65
87	Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. <i>International Journal of Clinical Practice</i> , 2002, 56, 494-9.	0.8	65
88	Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. <i>Diabetes Therapy</i> , 2019, 10, 1995-2021.	1.2	63
89	Obesity and diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 1999, 13, 221-237.	2.2	62
90	Thiazolidinediones, insulin resistance and obesity: finding a balance. <i>International Journal of Clinical Practice</i> , 2006, 60, 1272-1280.	0.8	62

#	ARTICLE	IF	CITATIONS
91	Plasma Adiponectin Increases Postprandially in Obese, but not in Lean, Subjects. <i>Obesity</i> , 2003, 11, 839-844.	4.0	61
92	Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. <i>International Journal of Obesity</i> , 2008, 32, 129-135.	1.6	60
93	Night eating syndrome: implications for severe obesity. <i>Nutrition and Diabetes</i> , 2012, 2, e44-e44.	1.5	60
94	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 973-982.	2.2	59
95	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. <i>Heart</i> , 2005, 91, 32-37.	1.2	58
96	Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease. <i>Diabetes Care</i> , 2014, 37, 483-487.	4.3	58
97	Science, medicine, and the future: Obesity treatment. <i>BMJ: British Medical Journal</i> , 1997, 315, 997-1000.	2.4	58
98	Abdominal Obesity, Impaired Nonesterified Fatty Acid Suppression, and Insulin-Mediated Glucose Disposal Are Early Metabolic Abnormalities in Families With Premature Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1021-1026.	1.1	57
99	Newer GLP-1 receptor agonists and obesity-diabetes. <i>Peptides</i> , 2018, 100, 61-67.	1.2	54
100	Risk of Misdiagnosis, Health-Related Quality of Life, and BMI in Patients Who Are Overweight With Doctor-Diagnosed Asthma. <i>Chest</i> , 2012, 141, 616-624.	0.4	53
101	SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. <i>Diabetes Therapy</i> , 2018, 9, 1757-1773.	1.2	53
102	E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. <i>Cancer Research</i> , 1996, 56, 5285-92.	0.4	53
103	Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. <i>Clinical Endocrinology</i> , 2009, 71, 195-201.	1.2	52
104	Exposure-response analyses of liraglutide 3.0 mg for weight management. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 491-499.	2.2	52
105	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1529-1536.	2.2	52
106	Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. <i>Chronic Respiratory Disease</i> , 2014, 11, 257-275.	1.0	51
107	Time for a new obesity narrative. <i>Lancet, The</i> , 2018, 392, 1384-1386.	6.3	50
108	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1805-1815.	4.3	49

#	ARTICLE	IF	CITATIONS
109	Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. <i>Diabetologia</i> , 1994, 37, 166-169.	2.9	47
110	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. <i>Clinical Science</i> , 2001, 100, 635-641.	1.8	47
111	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. <i>Clinical Science</i> , 2001, 101, 499-506.	1.8	47
112	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44
113	Sleep disordered breathing - a new component of syndrome x?. <i>Obesity Reviews</i> , 2001, 2, 267-274.	3.1	43
114	The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. <i>Diabetologia</i> , 2011, 54, 1304-1307.	2.9	43
115	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 438-444.	1.2	43
116	Impact of bariatric surgery on physical functioning in obese adults. <i>Obesity Reviews</i> , 2015, 16, 248-258.	3.1	42
117	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000700.	1.2	42
118	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 312, E224-E233.	1.8	41
119	Cardiovascular outcome trials in obesity: A review. <i>Obesity Reviews</i> , 2021, 22, e13112.	3.1	41
120	Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. <i>Journal of Endocrinology</i> , 1997, 152, 365-369.	1.2	40
121	Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. <i>Medicine and Science in Sports and Exercise</i> , 2019, 51, 1169-1177.	0.2	40
122	Clinical presentation of thyroid dysfunction and Addison's disease in young adults with type 1 diabetes. <i>Postgraduate Medical Journal</i> , 1999, 75, 467-470.	0.9	39
123	The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Peptides</i> , 2020, 125, 170208.	1.2	39
124	Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 194-203.	0.9	38
125	The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. <i>Journal of Psychopharmacology</i> , 2010, 24, 99-109.	2.0	38
126	Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide-1 and ghrelin in obese patients with Type-2 diabetes mellitus. <i>Diabetic Medicine</i> , 2012, 29, e205-10.	1.2	38

#	ARTICLE	IF	CITATIONS
127	Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradation. <i>Age</i> , 2010, 32, 209-222.	3.0	37
128	Effect of food deprivation and streptozotocin-induced diabetes on hypothalamic neuropeptide Y release as measured by a radioimmunoassay-linked microdialysis procedure. <i>Brain Research</i> , 1994, 656, 135-140.	1.1	36
129	Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. <i>Clinical Endocrinology</i> , 2003, 59, 75-81.	1.2	36
130	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016, 39, S154-S164.	4.3	36
131	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.	2.3	36
132	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. <i>Diabetes Therapy</i> , 2019, 10, 1595-1622.	1.2	36
133	Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. <i>British Journal of Pharmacology</i> , 2001, 132, 1898-1904.	2.7	35
134	Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. <i>Diabetic Medicine</i> , 2006, 23, 780-787.	1.2	35
135	Ghrelin restores "lean-type" hunger and energy expenditure profiles in morbidly obese subjects but has no effect on postgastrectomy subjects. <i>International Journal of Obesity</i> , 2009, 33, 317-325.	1.6	35
136	Medication use for the treatment of diabetes in obese individuals. <i>Diabetologia</i> , 2018, 61, 265-272.	2.9	35
137	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose cotransporter 2 inhibitor therapy in <sc>DECLARE-TIMI</sc> 58. <i>European Journal of Heart Failure</i> , 2021, 23, 1026-1036.	2.9	35
138	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. <i>Obesity Reviews</i> , 2018, 19, 1569-1584.	3.1	34
139	The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. <i>Clinical Endocrinology</i> , 2004, 60, 137-141.	1.2	33
140	Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. <i>Diabetologia</i> , 2005, 48, 2641-2649.	2.9	33
141	Assessing the cost-effectiveness of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	2.2	33
142	Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 299-303.	1.7	32
143	The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit?. <i>Thorax</i> , 2012, 67, 920-924.	2.7	32
144	GLP-1 as a target for therapeutic intervention. <i>Current Opinion in Pharmacology</i> , 2016, 31, 44-49.	1.7	32

#	ARTICLE	IF	CITATIONS
145	Leptin and the control of obesity. <i>Current Opinion in Pharmacology</i> , 2001, 1, 656-661.	1.7	31
146	Human RBP4 adipose tissue expression is gender specific and influenced by leptin. <i>Clinical Endocrinology</i> , 2011, 74, 197-205.	1.2	31
147	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.	1.2	31
148	Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. <i>Bone</i> , 2007, 41, 406-413.	1.4	30
149	Obstructive sleep apnoea in patients with type 2 diabetes: aetiology and implications for clinical care. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 733-741.	2.2	29
150	Acute peripheral administration of synthetic human GLP-1 (7â€“36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. <i>Regulatory Peptides</i> , 2013, 183, 54-61.	1.9	29
151	Combination therapy for obesity. <i>Journal of Psychopharmacology</i> , 2017, 31, 1503-1508.	2.0	28
152	Dapagliflozin plus saxagliptin addâ€“on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1094-1101.	2.2	28
153	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from <sc>DECLAREâ€“TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	2.2	28
154	Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLAREâ€“TIMI 58 trial. <i>European Heart Journal</i> , 2022, 43, 2958-2967.	1.0	28
155	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. <i>International Journal of Obesity</i> , 2021, 45, 923-933.	1.6	28
156	Intensified treatment of type 2 diabetesâ€“positive effects on blood pressure, but not glycaemic control. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 833-836.	0.2	27
157	Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. <i>Postgraduate Medical Journal</i> , 2007, 83, 277-280.	0.9	27
158	Treatment strategies for obesity. <i>Obesity Reviews</i> , 2007, 8, 137-144.	3.1	27
159	Obstructive sleep apnea is associated with increased arterial stiffness in severe obesity. <i>Journal of Sleep Research</i> , 2014, 23, 700-708.	1.7	27
160	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. <i>Annals of Medicine</i> , 2021, 53, 2072-2089.	1.5	27
161	Effects of insulin-induced hypoglycaemia on energy intake and food choice at a subsequent test meal. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 405-410.	1.7	26
162	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLAREâ€“TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1357-1368.	2.2	26

#	ARTICLE	IF	CITATIONS
163	The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. <i>Diabetologia</i> , 2021, 64, 288-303.	2.9	26
164	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 801.	3.0	26
165	Is There a Role for Ghrelin and Peptide-YY in the Pathogenesis of Obesity in Adults with Acquired Structural Hypothalamic Damage?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5025-5030.	1.8	25
166	A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2012, 77, 635-637.	1.2	25
167	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1159-1167.	4.3	25
168	Ghrelin inhibits autonomic function in healthy controls, but has no effect on obese and vagotomized subjects. <i>Clinical Endocrinology</i> , 2010, 73, 678-685.	1.2	24
169	Improved glycaemic control-an unintended benefit of a nurse-led cardiovascular risk reduction clinic. <i>Diabetic Medicine</i> , 2005, 22, 1272-1274.	1.2	23
170	Realising the full potential of data-enabled trials in the UK: a call for action. <i>BMJ Open</i> , 2021, 11, e043906.	0.8	23
171	Neurobiology. <i>British Medical Bulletin</i> , 1997, 53, 286-306.	2.7	22
172	Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 171-180.	2.2	22
173	Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. <i>European Journal of Endocrinology</i> , 2013, 168, 501-507.	1.9	22
174	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. <i>Primary Care Diabetes</i> , 2017, 11, 437-444.	0.9	22
175	Incorporating patients'™ perspectives into the initial stages of core outcome set development: a rapid review of qualitative studies of type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000615.	1.2	22
176	Abnormal Heart Rate Variability in Adults with Growth Hormone Deficiency1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 628-633.	1.8	21
177	Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. <i>Brain Research</i> , 2004, 1016, 222-228.	1.1	21
178	Screening for obstructive sleep apnoea in obesity and diabetes – potential for future approaches. <i>European Journal of Clinical Investigation</i> , 2013, 43, 640-655.	1.7	21
179	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016, 68, 606-613.	1.3	21
180	Should obesity be recognised as a disease?. <i>BMJ: British Medical Journal</i> , 2019, 366, l4258.	2.4	21

#	ARTICLE	IF	CITATIONS
181	SGLT2 inhibitors and urinary tract infections. <i>Nature Reviews Endocrinology</i> , 2019, 15, 687-688.	4.3	21
182	Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. <i>Clinical Science</i> , 2001, 101, 499.	1.8	20
183	Are the causes of obesity primarily environmental? Yes. <i>BMJ, The</i> , 2012, 345, e5843-e5843.	3.0	20
184	Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. <i>Diabetes Therapy</i> , 2016, 7, 695-711.	1.2	20
185	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2017, 71, e12948.	0.8	20
186	SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2757-2774.	1.2	20
187	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	4.3	20
188	Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 β -stimulated human white preadipocytes via modulating the NF- κ B and unfolded protein response pathways. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1049-1056.	1.0	19
189	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1020-1029.	2.2	19
190	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. <i>Diabetes Care</i> , 2022, 45, 2396-2405.	4.3	19
191	Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. <i>Clinical Science</i> , 2001, 100, 635.	1.8	18
192	The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2001, 54, 819-826.	1.2	18
193	Effects of S 15511, a therapeutic metabolite of the insulin-sensitizing agent S 15261, in the Zucker Diabetic Fatty rat. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 114-120.	2.2	18
194	Glucagon-like peptide-1 analogues for type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2011, 342, d410.	2.4	18
195	Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 2219-2221.	2.9	17
196	Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population. <i>Sleep Medicine</i> , 2013, 14, 1151-1156.	0.8	17
197	Liraglutide in the treatment of obesity. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1215-1224.	1.4	17
198	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 240-250.	1.1	17

#	ARTICLE	IF	CITATIONS
199	Obesity: under-diagnosed and under-treated in hospital outpatient departments. <i>International Journal of Obesity</i> , 2002, 26, 581-584.	1.6	16
200	Characteristics and perspectives of night-eating behaviour in a severely obese population. <i>Clinical Obesity</i> , 2014, 4, 30-38.	1.1	16
201	Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. <i>Experimental Physiology</i> , 2017, 102, 1424-1434.	0.9	16
202	Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. <i>Diabetes Therapy</i> , 2018, 9, 1791-1810.	1.2	16
203	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1122-1131.	2.2	16
204	Pathophysiology and aetiology of obesity. <i>Medicine</i> , 2015, 43, 73-76.	0.2	15
205	Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE) study protocol. <i>BMJ Open</i> , 2017, 7, e013539.	0.8	15
206	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 1226-1234.	2.9	15
207	Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β -cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. <i>International Journal of Experimental Pathology</i> , 2003, 84, 83-89.	0.6	14
208	How to approach endocrine assessment in severe obesity?. <i>Clinical Endocrinology</i> , 2013, 79, 163-167.	1.2	14
209	Urinary proteomics in obstructive sleep apnoea and obesity. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1104-1115.	1.7	14
210	Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. <i>International Journal of Clinical Practice</i> , 2015, 69, 186-198.	0.8	14
211	Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea. <i>Sleep and Breathing</i> , 2015, 19, 1155-1165.	0.9	14
212	Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. <i>Journal of Obesity</i> , 2016, 2016, 1-12.	1.1	14
213	SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials. <i>Trials</i> , 2017, 18, 597.	0.7	14
214	Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenological study. <i>Nutrition and Metabolism</i> , 2007, 4, 15.	1.3	13
215	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
216	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13

#	ARTICLE	IF	CITATIONS
217	Evaluation of Aintree <sc>LOSS</sc>, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement. <i>Clinical Obesity</i> , 2017, 7, 368-376.	1.1	12
218	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. <i>Trials</i> , 2018, 19, 427.	0.7	12
219	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020, 36, 571-581.	0.9	12
220	Clinical Evaluation of Anti-Obesity Drugs. <i>Current Drug Targets</i> , 2004, 5, 325-332.	1.0	12
221	Reduced NPY Induced Feeding in Diabetic but not Steroid-Treated Rats: Lack of Evidence for Changes in Receptor Number or Affinity. <i>Journal of Neuroendocrinology</i> , 1996, 8, 283-290.	1.2	11
222	From history to reality: sodium glucose co-transporter 2 inhibitors â€œ a novel therapy for type 2 diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2010, 27, 311-316.	0.2	11
223	Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. <i>European Journal of Endocrinology</i> , 2011, 165, 45-55.	1.9	11
224	Fit for <sc>B</sc>irth â€œ the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study. <i>Clinical Obesity</i> , 2016, 6, 79-88.	1.1	11
225	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. <i>Diabetes Therapy</i> , 2019, 10, 2201-2217.	1.2	11
226	Strengthening resistance to the COVID-19 pandemic and fostering future resilience requires concerted action on obesity. <i>Global Health Action</i> , 2020, 13, 1804700.	0.7	11
227	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. <i>Diabetes</i> , 2019, 68, 244-OR.	0.3	11
228	Exercise in Obesityâ€”the Role of Technology in Health Services: Can This Approach Work?. <i>Current Obesity Reports</i> , 2022, 11, 93-106.	3.5	11
229	Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. <i>European Journal of Pharmacology</i> , 2001, 416, 133-139.	1.7	10
230	Obesity and Type-2 Diabetes in the Elderly. <i>Gerontology</i> , 2003, 49, 137-145.	1.4	10
231	Growth hormone and changes in energy balance in growth hormone deficient adults. <i>European Journal of Clinical Investigation</i> , 2008, 38, 622-627.	1.7	10
232	Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. <i>Endocrine</i> , 2013, 43, 696-704.	1.1	10
233	Serum urate and obstructive sleep apnoea in severe obesity. <i>Chronic Respiratory Disease</i> , 2015, 12, 238-246.	1.0	10
234	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. <i>Clinical Obesity</i> , 2018, 8, 211-225.	1.1	10

#	ARTICLE	IF	CITATIONS
235	SGLT2 inhibition and ketoacidosis “ should we be concerned?. British Journal of Diabetes and Vascular Disease, 2015, 15, 155.	0.6	10
236	Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. European Journal of Endocrinology, 2020, 183, 211-220.	1.9	10
237	Endocrine testing in obesity. European Journal of Endocrinology, 2020, 182, C13-C15.	1.9	10
238	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care, 2022, 45, e27-e29.	4.3	10
239	Energy restriction enhances therapeutic efficacy of the PPAR γ agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes, Obesity and Metabolism, 2008, 10, 251-263.	2.2	9
240	Orlistat: should we worry about liver inflammation?. BMJ, The, 2013, 346, f2777-f2777.	3.0	9
241	Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 141-147.	1.8	9
242	Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea“hypnoea index (AHI). BMJ Open, 2020, 10, e038856.	0.8	9
243	Mechanisms, screening modalities and treatment options for individuals with non“alcoholic fatty liver disease and type 2 diabetes. Diabetic Medicine, 2020, 37, 1793-1806.	1.2	9
244	Acute Effects of Central Neuropeptide Y Injection on Glucose Metabolism in Fasted Rats. Clinical Science, 1995, 89, 543-548.	1.8	8
245	Body weight and prolactinoma: a retrospective study. International Journal of Obesity, 2004, 28, 183-183.	1.6	8
246	Pathophysiology and aetiology of obesity. Medicine, 2006, 34, 501-505.	0.2	8
247	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula performs worse than the Modification of Diet in Renal Disease (MDRD) equation in estimating glomerular filtration rate in Type“2 diabetic chronic kidney disease. Diabetic Medicine, 2011, 28, 1279-1279.	1.2	8
248	Pathophysiology and aetiology of obesity. Medicine, 2011, 39, 6-10.	0.2	8
249	Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opinion on Emerging Drugs, 2013, 18, 375-391.	1.0	8
250	A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. Expert Opinion on Drug Safety, 2014, 13, 1535-1544.	1.0	8
251	Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. Clinical Science, 2014, 127, 655-663.	1.8	8
252	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6“10. Diabetes Care, 2018, 41, e106-e108.	4.3	8

#	ARTICLE	IF	CITATIONS
253	Dapagliflozin for the treatment of type 2 diabetes mellitus – an update. Expert Opinion on Pharmacotherapy, 2021, 22, 2303-2310.	0.9	8
254	A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ Open, 2021, 11, e045663.	0.8	8
255	Anti-obesity Drugs: From Animal Models to Clinical Efficacy. , 2008, , 271-315.		7
256	In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF. Diabetes, Obesity and Metabolism, 2010, 12, 360-363.	2.2	7
257	Nurse-led clinics for strict hypertension control are effective long term: a 7-year follow-up study. Diabetic Medicine, 2010, 27, 933-937.	1.2	7
258	Role of incretin-based therapies and sodium-glucose co-transporter inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. Diabetic Medicine, 2016, 33, 864-876.	1.2	7
259	Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. Appetite, 2018, 125, 270-277.	1.8	7
260	Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. Sleep Science, 2015, 8, 58-67.	0.4	6
261	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. Lancet Diabetes and Endocrinology, the, 2016, 4, 379-381.	5.5	6
262	Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq0 0 0 fBT /Overlock 10 T	1.6	6
263	Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2019, 155, 107791.	1.1	6
264	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. Future Cardiology, 2020, 16, 77-88.	0.5	6
265	Short-Term Physical Inactivity Induces Endothelial Dysfunction. Frontiers in Physiology, 2021, 12, 659834.	1.3	6
266	Obstructive sleep apnoea in diabetes - assessment and awareness. British Journal of Diabetes and Vascular Disease, 2014, 14, 105.	0.6	6
267	Adipokines: emerging therapeutic targets. Current Opinion in Investigational Drugs, 2009, 10, 1061-8.	2.3	6
268	Metabolic actions of neuropeptide Y and their relevance to obesity. Biochemical Society Transactions, 1996, 24, 576-581.	1.6	5
269	Response: Postprandial Adiponectin Revisited. Obesity, 2004, 12, 1032-1034.	4.0	5
270	Obesity and risk of myocardial infarction: the INTERHEART study. Lancet, The, 2006, 367, 1053.	6.3	5

#	ARTICLE	IF	CITATIONS
271	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. <i>BMJ Open</i> , 2020, 10, e034137.	0.8	5
272	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. <i>Diabetes Therapy</i> , 2022, 13, 847-872.	1.2	5
273	The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The <sc>SEESAW</sc> randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1509-1521.	2.2	5
274	Management of hypertension. <i>BMJ: British Medical Journal</i> , 2000, 320, 576-576.	2.4	4
275	Clinical Investigations of Antiobesity Drugs. , 2007, , 337-III.		4
276	Modern management of obesity. <i>Clinical Medicine</i> , 2009, 9, 617-621.	0.8	4
277	The clinical management of diabetes mellitus. , 2014, , 305-332.		4
278	Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study. <i>International Journal of Obesity</i> , 2015, 39, 1376-1382.	1.6	4
279	Screening methods for obstructive sleep apnoea in severely obese pregnant women. <i>Clinical Obesity</i> , 2017, 7, 239-244.	1.1	4
280	Metabolically healthy obesity: time for a change of heart?. <i>Nature Reviews Endocrinology</i> , 2021, 17, 519-520.	4.3	4
281	Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat <sc>MRI</sc> substudy. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 61-71.	2.2	4
282	Vitamin D3 analogues ZK159222 and Zk191784 have anti-inflammatory properties in human adipocytes. <i>Endocrinology Metabolism & Genetics</i> , 2016, 1, .	0.0	4
283	Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-”The Energize Study. <i>Diabetes</i> , 2018, 67, .	0.3	4
284	Pharmacological Approaches for Treating Obesity. , 0, , 421-446.		3
285	Weighing up dietary patterns -” Authors' reply. <i>Lancet, The</i> , 2016, 388, 759-760.	6.3	3
286	Weight loss is the major player in bariatric surgery benefits. <i>Nature Medicine</i> , 2020, 26, 1678-1679.	15.2	3
287	Glucose metabolism and the pathophysiology of diabetes mellitus. , 2014, , 273-304.		3
288	1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. <i>Diabetes</i> , 2020, 69, 1101-P.	0.3	3

#	ARTICLE	IF	CITATIONS
289	The future of obesity treatment. <i>Exs</i> , 2000, 89, 181-191.	1.4	3
290	Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?. <i>Diabetic Medicine</i> , 2005, 22, 666-667.	1.2	2
291	Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 170-176.	0.6	2
292	Facing the Challenges for Europe – Research into Action: Liverpool European Congress of Obesity, May 12–15, 2013. <i>Obesity Facts</i> , 2012, 5, 629-634.	1.6	2
293	Research update for articles published in <sc>EJCI</sc> in 2014. <i>European Journal of Clinical Investigation</i> , 2016, 46, 880-894.	1.7	2
294	Semaglutide in weight management – Author's reply. <i>Lancet, The</i> , 2019, 394, 1226-1227.	6.3	2
295	1 α ,25(OH) $_2$ D $_3$ attenuates IL-6 and IL-1 β -mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF- κ B signaling pathways. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 9.	1.2	2
296	DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1.	1.2	2
297	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021, 81, 1243-1255.	4.9	2
298	Endocrine effects of gastrointestinal tumours. <i>Endocrine-Related Cancer</i> , 1997, 4, 179-189.	1.6	1
299	Obesity and Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2000, 17, 400-402.	1.2	1
300	Ghrelin: sweet regulation?. <i>Clinical Science</i> , 2002, 103, 329-330.	1.8	1
301	Pathophysiology and Aetiology of Obesity. <i>Medicine</i> , 2003, 31, 1-4.	0.2	1
302	Diabetes and sleep apnoea: a hidden epidemic?. <i>Thorax</i> , 2006, 61, 928-929.	2.7	1
303	Blood pressure control and ACE inhibitor/angiotensin receptor blocker usage. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2008, 25, 54-58.	0.2	1
304	Obesity as a disability: a weighty precedent?. <i>Clinical Obesity</i> , 2015, 5, 163-164.	1.1	1
305	Etiopathogenesis of Obesity. , 2016, , 13-20.		1
306	SAT0209 – Observational study on the effects of il-6 inhibitor therapy on myostatin in patients with rheumatoid arthritis. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
307	The 1 α ,25(OH) ₂ D ₃ Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF- κ B and MAPK Signaling. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1715-1724.	1.1	1
308	1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. Diabetes, 2019, 68, .	0.3	1
309	303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial. Diabetes, 2020, 69, .	0.3	1
310	PARIS: protocol for a prospective single arm, theory-based, group-based feasibility intervention study to increase Physical Activity and reduce sedentary behaviour after bariatric Surgery. BMJ Open, 2021, 11, e051638.	0.8	1
311	Elevated hypothalamic neuropeptide-Y concentrations in rats fed a palatable diet – effect of d-fenfluramine. Regulatory Peptides, 1990, 30, 59.	1.9	0
312	Necrolytic migratory erythema: a classical cutaneous presentation of the glucagonoma syndrome. Journal of the European Academy of Dermatology and Venereology, 1997, 9, 68-73.	1.3	0
313	Sympathovagal Balance in Growth Hormone Deficient Patients. Clinical Science, 1999, 97, 6P-6P.	0.0	0
314	Evolution of Early Changes in Heart Rate Variability following Acute Myocardial Infarction. Clinical Science, 2000, 99, 15P-16P.	0.0	0
315	Abnormal heart rate variability in adults with symptomatic growth hormone (GH) deficiency: improvement after 3 months of GH replacement therapy. Growth Hormone and IGF Research, 2000, 10, S149.	0.5	0
316	Peripheral Injection Of Risperidone, An Atypical Antipsychotic, Alters The Body Weight Gains Of Rats. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 513-514.	0.9	0
317	Obesity treatment: the key to managing the type 2 diabetes timebomb?. British Journal of Diabetes and Vascular Disease, 2004, 4, 217-219.	0.6	0
318	Applied physiology: The control of weight. Current Paediatrics, 2006, 16, 439-446.	0.2	0
319	An elderly type 1 diabetic patient with life event-related brittle diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 130-131.	0.2	0
320	Identification of macrophage inhibitory cytokine-1 (MIC-1) in adipose tissue and its secretion as an adipokine by human adipocytes. Proceedings of the Nutrition Society, 2009, 68, .	0.4	0
321	The adipokine zinc- α 2-glycoprotein is down regulated with fat mass expansion in obesity. Proceedings of the Nutrition Society, 2009, 68, .	0.4	0
322	The endocrinologist and respiratory failure. , 2010, , 391-398.		0
323	High-fat diet-induced obesity is associated with increased cardiac telomerase expression but not cell proliferation in the rat. Proceedings of the Nutrition Society, 2012, 71, .	0.4	0
324	Reply to Camargo <i>et al</i> . Diabetic Medicine, 2012, 29, 1086-1087.	1.2	0

#	ARTICLE	IF	CITATIONS
325	Canagliflozin (CANA) Lowers A1C and Blood Pressure (BP) Through Weight Loss-Independent (WL-I) and Weight Loss-Associated (WL-A) Mechanisms. Canadian Journal of Diabetes, 2013, 37, S29.	0.4	0
326	232 DIFFERENTIAL GENETIC EXPRESSION AND REDUCED LONGITUDINAL FUNCTION IN PATIENTS WITH DIABETES AND SEVERE AORTIC STENOSIS WITH A NORMAL EJECTION FRACTION. Heart, 2013, 99, A125.1-A125.	1.2	0
327	An observation of gestational weight gain in obese pregnancies. Proceedings of the Nutrition Society, 2015, 74, .	0.4	0
328	Obesity and Obstructive Sleep Apnea Syndrome. Endocrinology, 2018, , 1-30.	0.1	0
329	410Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus. European Heart Journal, 2019, 40, .	1.0	0
330	Cover Image, Volume 22, Issue 7. Diabetes, Obesity and Metabolism, 2020, 22, .	2.2	0
331	Design of a randomised controlled trial: does indirect calorimetry energy information influence weight loss in obesity?. BMJ Open, 2021, 11, e044519.	0.8	0
332	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). Journal of the Endocrine Society, 2021, 5, A10-A10.	0.1	0
333	P953 The evolution of heart rate variability patterns following acute myocardial infarction in the post-thrombolytic era. European Heart Journal, 2003, 24, 159.	1.0	0
334	HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in U.K. Primary Care Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	0
335	A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin. Diabetes, 2018, 67, 1131-P.	0.3	0
336	Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. Diabetes, 2018, 67, .	0.3	0
337	Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program. Diabetes, 2018, 67, 1191-P.	0.3	0
338	Intestinal lipase inhibitors. , 2008, , 47-57.		0
339	The endocannabinoid system as a target for obesity treatment. , 2008, , 69-80.		0
340	Etiopathogenesis of Obesity. , 2021, , 1-12.		0
341	Drug Therapy for the Obese Diabetic Patient. , 0, , 185-202.		0